# A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

> **NCT05668585** · PHASE1 · COMPLETED · sponsor: **C4 Therapeutics, Inc.** · enrollment: 89 (actual)

## Conditions studied

- Solid Tumors
- Melanoma
- NSCLC
- CRC
- ATC

## Interventions

- **DRUG:** CFT1946
- **DRUG:** Trametinib
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT05668585
- **Lead sponsor:** C4 Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-08
- **Primary completion:** 2025-11-05
- **Final completion:** 2025-11-05
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05668585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05668585, "A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05668585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*